... ,
`
`Lll__
`
`'
`
`Volume 155
`
`May 1996
`
`Number 5
`
`~- ------------------~~------------------------------
`'~)
`The ournal of
`
`~ 0
`~ _..;
`.
`:
`~ ~'
`~ \Jli
`~ Ul.
`I
`~ I 5
`I
`i.n
`------------------------------------------------
`~
`~.~ -~,
`I ~.
`AUA Ninety-First Annual Meeting
`:J o!
`May 4-9, 1996
`~ I
`
`®
`
`~
`
`May 1996
`
`-
`
`I
`
`American
`Urological
`Association
`
`May 4-9
`
`WESTON LIBRARY
`APR 1 61996
`
`JS/1<9 l;l.miCA.~ SCIENGES CENTER
`liOO IHGlllA~~ AV-MADISON, wt 53712
`
`Supplement to the Journal of Urology
`
`ATI 1026-0001
`
`ATI v. ICOS
`IPR2018-01183
`
`

`

`Table of Contents
`
`Board of Directors ................................................................................ 9
`Committees ............................................................ -................. ~ ...... 10
`Local Arril:ngements ......................................................................... 10
`Program .................................................................................. 10
`Prize Essay ................................................................................ 10
`Public Media .............................................................................. 10
`Audio Visual .............................................................................. 10
`Program Abstract Review ..........................................................•.......... 11
`Ambrose Reed Socioeconomic ......................................................•. · ......... 11
`General Information ............................................................................. 12
`Social Functions .....................................................................•.......... 18
`Youth Programs ......................................................................•.......... 21
`Tours ......................................................................................... 22
`Corporate Patrons/Contributors ...................................................................... 25
`Convention Floor Plan ......................... : .................................................. 29
`Exhibit Floor Plan ............................................................................... 32
`Peabody Floor Plan .............................................................................. 3
`Omni Rosen Floor Plan .................................................................. ·- ........ 3
`Subspecialty Programs ............................................................................ 3
`Genitourinary Reconstructive Surgeons ........................................................... 3
`Society for Pediatric Urology ................................................................... 3
`Urodynamics Society ........................................................................ 41
`Society for the Study of Male Reproduction ......................... · .. .' ............................ 4
`ICUD/WHO Consultation CA Prostate ............................................................ 4
`Society for Basic Urologic Research ............................................................. 4
`Society for Urology and Engineering ............................................................. 4
`Joint Program of the American Urological Association and the Conferderac;ion Americana de Urologia ............ 4
`Society for the Study of Impotence .............................................................. 4
`Society of Urologic Oncology .................................................................. 5
`American Foundation for Urologic Disease Research Scholar Program ......................................... 5
`American Association of Clinical Urologists ............................................................. 5
`Meeting Overview ............................................................................... 5
`Sunday's Sessions ........................................................................... 7
`Monday's Segsions ......................................................................... 12
`Tuesday's SesSions ......................................................................... 16
`Wedne~day's Sessions ....................................................................... 20
`Thursday's Session .. , ......................................................................... 23
`Office of Education coUrses by Dat~ ~nd Time ......................................................... 23
`Office of Education Courses by Category ............................................................. 24
`Video Forum .................................................................................. 25
`Video Library .................................................................................. 26
`1995-1996 AUA Awards ......................................................................... 26
`Exhibitors Product Category by Listing ............................................................... 26
`Exhibitors Product Service by Listing ................................................................. 27
`Abstracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`. ........................................... 28
`Index of Authors/Participants
`. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`. . . . . . . . . . . . . . .
`. ......... 71
`Subject Index of Abstracts
`. . . . . . . . .
`. . . . . . . . .
`. . . . . . . . . . . . . . . .
`. .............................. 76
`Index of Advertisers . . . . . . . . . . . . . . . . . . . . . . . . . .
`. ............................................... 78
`
`Important: The number preceding the title of a presentation is the abstract number.
`
`ISSN 0022-5347
`AUA Program
`Copyright© 1996 American Urological Association, Inc.
`(issued by Library of Congress)
`Price $25 per copy
`
`4
`
`ATI 1026-0002
`
`

`

`736
`CLINICAL OUTCOME OF T1 BLADDER CANCER. l\liguel Antelo,
`Colin P. Dinney and H. Barton Grossman, Houston, TX
`(Presentation by Dr. Antelo)
`INTRODUCTION AND OB;JECTIVES: Patients with Tl bladder
`cancer harbor neoplasms with documented invasive potential. We
`evaluated the therapeutic inten•entions and clinical outcome in 89
`patients with Tl disease.
`METHODS: Eligible patients had T1 bladder cancer diagnosed at
`the University of Texas MD Anderson Cancer Cente;· from August,
`1975 through April, 1994 who had follow -up data. 89 patients met
`these criteria and had a mean and median follow-up of 4.1 and 3.4
`years respectively (range 0.9 to 19.9 years). Treatment included
`transurethral resection, intravesical chemotherapy, BCG, and/or
`cystectomy.
`RESULTS: The mean s urvival for all 89 patients was 12.6 years.
`The 5 and 10 year survival rates were 69% and 54% respectively.
`The rates of recurrence and pro(p:ession were 40% and 26%
`respectively. The recurrence and progression rates for 36 patients
`receiving BCG were 42% and 22% respectively. 35 patients were
`treated with cystectomy (21 early and 14 delayed). Progression (P)
`and death from bladder cancer (D) occurred in patients treated with
`both early (5P, 3D) and delayed cystectomy (7P, 3D).
`Median
`Confidence Bladder Ca
`# Pts.
`Survival
`Interval
`Deaths
`8.7 years
`7.1. 10.3
`17%
`54
`No Cystectomy
`8.9. 10.7
`9.8 years
`17%
`Cystectomy
`35
`CONCLUSIONS: Most patients w1th T l bladder cancer have a
`long survival.
`Cystectomy does not afford protection
`from
`progression and death from bladder cancer and does not improve
`survival. Patients presenting with T1 bladder cancer need careful
`monitoring with aggressive
`therapy (cystectomy)
`reserved
`for
`recurrent invasive bladder cancer or disease refractory to local
`therapy.
`Supported in part by grant UO I·CA56973 from NCI, NIH.
`
`737
`UK-92,480, A NEW ORAL THERAPY FOR ERECTll.E DYSFUNCTION, A
`DOUBLE-BLIND, PLACEBO CONTROLLED TIUAL WITH TREATMENT
`TAKEN AS REQUIRED
`ian Eardley (Leeds, UK). Roben J Morgan (London. UK). Wallace W Dinsmore
`(Belfas~ UK). Josephine Pearson. Maria B Wulff, Mitradev BooleU (Sandwich, UK).
`(J>resen~1tion by Mr 1 Eardley).
`INTRODUCTION AND OBJECTIVES
`Nilric oxide, via cGMP, is critical for U1e relaxation of the corpus cavcmosum. a key
`factor in penile erection. UK-92,480 is an orally active potent i~_ibitor of type V
`cGMP-specific PDE. the predominant isoenzyme in the human corpus cavemosum
`and as such has the potential to enhance penile erectile activity. The efficacy and
`safety of UK-92.480 in improving erectile activity was evaluated in patienLS with
`MED without an established organic cause.
`METHODS
`42 patienLS with a mean age of 53 years (range 34 · 70) a mean duration of MED of
`3 years (range 0.5 . 10) took placebo or UK-92,480 (25, 50 or 75mg) as required for
`28 days in a double blind. randomised, two-way. crossover study.
`REsULTS
`Of the patienLS with complete efficacy data, 34/37 (92%) reponed an improvement
`in the quality of erections on UK-92,480 compared lO 10/37 (27%) on placebo
`(p <0.0001). Tbis was conftrmed by the patienLS partner: 33/36 (91 %) felL U1aL there
`was an improvement in their partners erection on UK-92,480 compared to 7/36
`(19%) on placebo (p <0.0001). The mean number of erections which were
`sufficiently rigid for penetrative sexual intercourse over 28 days was 18.4 ( 14 · 24.3,
`95% confidence interval) on UK-92,480 compared to 5.6 (4.1 • 7.4) on placebo
`(p <0.0001). The frequency of use of UK-92,480 was 12.5 doses over 28 days
`compared to 8.6 for placebo. In general UK-92.480 was well tolerated, the most
`commonly reponed adverse evenLS were headache. dyspepsia and muscle aches
`which were mild and transient.
`CONCLUSIONS
`The data demonstrate that UK-92.480 is efficacious in improving erectile activity in
`patienLS with MED without an established cause and may represent an aumctive oral
`therapy for Ulis condition.
`
`738
`UK-92,480 , A NEW ORAL TREATMENT FOR ERECTILE DYSFUNCTION: A
`DOUBLE-BLIND, PLACEBO-CONTROLLED, ONCE DAILY DOSE RESPONSE
`STUDY. Clive J C Gingell, Bristol, UK; Alain Jardin, Paris,
`France; Arne ~t Olsson, Lund, Sweden; Wallace W Dinsmore,
`Belfast, UK; Ian H Osterloh, John Kirkpatrick, Michelle
`Cuddigan , Sandwich, UK; an<' the ~tulticentre Study Group.
`(Presentation by Dr Gingell).
`INTRODUCTION: It is now recognised that penile erection is
`mediated by the action of nitric oxide /cG~W (cyclic guano(cid:173)
`sine monophosphate). UK-92,480 is a selective inhibitor of
`Type 5 phosphodiesterase, the predominant isoenzyme causing
`breakdown of cG~W in the human corpus cavernosum.
`METHODS: This trial (protocol 148-353) recruited 351 male
`patients (mean age 53, range 24-70 years) with erectile dys(cid:173)
`function (ED) of no known organic cause . After a 2-week run(cid:173)
`in on no treatment, patients were randomly allocated to re(cid:173)
`ceive oral capsules of lOmg, 25mg or 50mg of UK-92,480 or
`double-blind placebo administered once daily f or 28 con(cid:173)
`secutive days. Efficacy instruments included patient asses s(cid:173)
`ment of whether treatment improved erections, a 15-item
`self-administered sexual function questionnaire (SFQ), and
`diary records of erections.
`RESULTS: The proportions of patients reporting that treat(cid:173)
`ment had improved their erections were 38% (placebo), ~5%
`( 10mg), 79% (2Smg) and 89% (50mg) (p for treatment effect
`<0.001) . SFQ analyses showed similar dose-response relation(cid:173)
`ships for frequency, hardness and duration of erections (p
`<0 .001) and other parameters of sexual funct i on including
`number of satisfactory intercourses and quality of sex life.
`UK-92,480 treatment was generally well-tolerated. Head(cid:173)
`ache, flushing, dyspepsia and muscle aches were reported
`more times than other adverse events. The overall propor(cid:173)
`tion of patients discontinuing treatment because of adverse
`events was less than 5% and the proportions were similar for
`all treatment groups.
`CONCLUSIONS: The results indicate tbat UK-92,480 is an
`effective, well-tolerated, oral treatment of ED in patients
`with no known organic cause.
`
`739
`FOR ERECTILE
`TREATMENT
`UK-92,480, A NEW ORAL
`DYSFUNCTION.
`A DOUBLE-BLIND, PLACEBO CONTROLLED
`CROSSOVER STUDY DEMONSTRATING DOSE RESPONSE WITH
`RIGISCAN AND EFFICACY WITH OUTPATIENT DIARY. Mitradev
`Boolell (Sandwich UK), Sam Gepi-Attee & Clive Gingell (Bristol UK)
`and Michael Allen (Sandwich UK) (Presented by Clive Gingell).
`INTRODUCTION AND OBJECTIVES: Male erectile dysfunction (MED) is
`a common cond~ion for which there is no satisfactory oral therapy. Recent
`studies suggest thai erection is dependent on n~ric oxide and its second
`messenger, cyclic guanosine monophosphale (cGMP). UK-92,480 is a
`potent selective inhibitor of type 5 (cGMP·spec~ic) phosphodieslemse, the
`predominant isoenzyme in the human corpus cavernosum. UK-92,480 was
`evaluated in patients w~h MED w~houl an established organic cause.
`METHODS: 12 patients entered a double blind randomised placebo
`controlled crossover study.
`In the first phase (4-way crossover) efficacy
`was evaluated by the duration of penile rigidity (RigiScan) during 2 hours of
`visual sexual stimulation following single doses of UK-92,480 (10mg, 25mg,
`50mg and placebo). In the second phase (2-way crossover) efficacy was
`assessed by a diary record of erectile acliv~y following daily doses of
`UK-92,480 (25mg) and placebo for 7 days.
`RESULTS: Mean duration of rigidity >80% (in minutes) al the base of
`the penis was 1.3 (95% confidence Interval, 0.4·3.1) on placebo, 3.5
`(1.6·7.3) on 10mg (p:0.095), 8.0 (3.7·16.7) on 25mg (p=0.003), and 11.2
`(5.6·22.3) on 50mg (p=0.0004). Corresponding values at the lip of the
`penis were 1.2 (0.4·2.7) on placebo, 4.6 (2.4·8.5) on 10mg (p=0.014). 6.9
`(3.5·13.1) on 25mg (p=0.002), and 7.4 (3.9·13.4) on 50mg (p=0.001).
`From the diary, the mean number of erections of sufficient rigidity for
`penetrative sexual intercourse was 6.1 (3.2·11.4) on UK-92,480 and 1.3
`(0.5·2.7) on placebo. 10/12 patients reported improved erectile aclivity on
`UK-92,480 compared to 2/12 on placebo (p = 0,018). Six patients on active
`trea tment and five on placebo reported mild and transient adverse events.
`CONCLUSIONS: UK-92,480 is a well tolerated and efficacious otal
`therapy forMED and represents a new class of peripherally acting drugs for
`the treatment of this condition.
`
`PROCEEDINGS OF THE AMERICAN UROLOGICAL ASSOCIATION
`VOLUME 155 • MAY 1996 SUPPLEMENT
`495A
`
`ATI 1026-0003
`
`